JP2022545553A5 - - Google Patents

Info

Publication number
JP2022545553A5
JP2022545553A5 JP2022513477A JP2022513477A JP2022545553A5 JP 2022545553 A5 JP2022545553 A5 JP 2022545553A5 JP 2022513477 A JP2022513477 A JP 2022513477A JP 2022513477 A JP2022513477 A JP 2022513477A JP 2022545553 A5 JP2022545553 A5 JP 2022545553A5
Authority
JP
Japan
Application number
JP2022513477A
Other languages
Japanese (ja)
Other versions
JPWO2021041989A5 (https=
JP2022545553A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048635 external-priority patent/WO2021041989A1/en
Publication of JP2022545553A publication Critical patent/JP2022545553A/ja
Publication of JPWO2021041989A5 publication Critical patent/JPWO2021041989A5/ja
Publication of JP2022545553A5 publication Critical patent/JP2022545553A5/ja
Priority to JP2025084157A priority Critical patent/JP2025124708A/ja
Pending legal-status Critical Current

Links

JP2022513477A 2019-08-29 2020-08-28 A型インフルエンザ感染の治療のための組成物及び方法 Pending JP2022545553A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025084157A JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893747P 2019-08-29 2019-08-29
US62/893,747 2019-08-29
US202062993519P 2020-03-23 2020-03-23
US62/993,519 2020-03-23
US202063040966P 2020-06-18 2020-06-18
US63/040,966 2020-06-18
PCT/US2020/048635 WO2021041989A1 (en) 2019-08-29 2020-08-28 Compositions and methods for treatment of influenza a infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025084157A Division JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022545553A JP2022545553A (ja) 2022-10-27
JPWO2021041989A5 JPWO2021041989A5 (https=) 2023-09-04
JP2022545553A5 true JP2022545553A5 (https=) 2023-09-04

Family

ID=72473986

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513477A Pending JP2022545553A (ja) 2019-08-29 2020-08-28 A型インフルエンザ感染の治療のための組成物及び方法
JP2025084157A Pending JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025084157A Pending JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Country Status (11)

Country Link
US (1) US20220306728A1 (https=)
EP (1) EP4021502A1 (https=)
JP (2) JP2022545553A (https=)
KR (1) KR20220061999A (https=)
CN (1) CN115052630A (https=)
AU (1) AU2020335922A1 (https=)
BR (1) BR112022003529A2 (https=)
CA (1) CA3148990A1 (https=)
IL (1) IL290752B2 (https=)
MX (1) MX2022002447A (https=)
WO (1) WO2021041989A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
RU2529951C2 (ru) * 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
BRPI0914092B1 (pt) 2008-10-22 2021-08-31 Institute For Research In Biomedicine Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
US10894083B2 (en) * 2015-01-28 2021-01-19 Pfizer Inc. Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
WO2017123685A1 (en) * 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
WO2019222674A1 (en) * 2018-05-18 2019-11-21 Chan Zuckerberg Biohub, Inc. Epitope restriction for antibody selection
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Similar Documents

Publication Publication Date Title
JP2022545553A5 (https=)
CN305936726S (https=)
CN305531116S (https=)
CN305561815S (https=)
CN305561136S (https=)
CN305557843S (https=)
CN305557124S (https=)
CN305556226S (https=)
CN305552946S (https=)
CN305550533S (https=)
CN305549198S (https=)
CN305534002S (https=)
CN305548727S (https=)
CN305529377S (https=)
CN305528475S (https=)
CN305646485S (https=)
CN305647260S (https=)
CN305533480S (https=)
CN305533428S (https=)
CN305533123S (https=)
CN305532889S (https=)
CN305938685S (https=)
CN305532779S (https=)
CN305648289S (https=)
CN305532743S (https=)